Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis-Reference-Cited by-同舟云学术

Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis

Published:2023-12-16 Issue:2 Volume:29 Page:213-221
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Shimomura Tatsuya^ORCID,Mori Keiichiro,Yasue Keiji,Matsukawa Akihiro,Fukuokaya Wataru,Yanagisawa Takafumi,Hata Kenichi,Murakami Masaya,Koike Yusuke,Miki Jun,Yamada Hiroki,Kimura Takahiro

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-023-02441-8.pdf

Reference30 articles.

1. Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3):581–592

2. Siegel R, DeSantis C, Virgo K et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62(4):220–241

3. Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59(4):572–583

4. Tran C, Ouk S, Clegg NJ et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787–790

5. Leibowitz-Amit R, Joshua AM (2012) Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress and future directions. Curr Oncol 19(Suppl 3):S22–S31

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abiraterone Acetate Versus Enzalutamide Against Chemo-Naïve Castration-Resistant Prostate Cancer With Full-Dose Induction;Cureus;2024-07-10

2. Abiraterone acetate versus enzalutamide against chemo-naïve castration resistant prostate cancer with full dose induction;2024-04-18